Skip to main content
S&P 5007,608.45+0.30%DOW51,975.40-0.23%NASDAQ26,155.26+0.67%BTC$75,506.00-1.21%ETH$2,387.22-2.55%GOLD$4,378.80+1.06%OIL$103.26-2.43%
Smart Investors Daily
MB

NASDAQ · MBAI

Check-Cap Ltd. Ordinary Share

Healthcare · Medical - Diagnostics & Research

$6.49

Up+$0.19 (+3.02%)

Updated Sep 16, 2026, 12:23 PM

SID Score

5.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
10.47M
P/E ratio
-0.42
Dividend yield
0.00%
52-week range
$0.95 – $10.48
Volume
22.4K
Avg. volume
3.04M

Price performance

MBAI price history

1M range · 20 trading sessions · Daily adjusted prices

MBAI closed at $6.49 after 20 trading sessions, down 22.37% for the selected period.

Last close
$6.49
Period change
-22.37%
Period low
$6.30
Period high
$8.36
Daily close
View OHLC price history
MBAI OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 15, 2026$6.30$6.49$6.23$6.4922.4K
Sep 14, 2026$6.36$6.39$6.30$6.304.46K
Sep 11, 2026$6.50$6.59$6.22$6.4031.41K
Sep 10, 2026$6.37$6.80$6.12$6.6063.66K
Sep 9, 2026$6.40$6.43$6.22$6.4226.38K
Sep 8, 2026$6.44$6.70$6.26$6.36550.03K
Sep 4, 2026$6.46$6.52$6.28$6.5021.3K
Sep 3, 2026$6.58$6.58$6.22$6.5051.86K
Sep 2, 2026$6.48$6.64$6.01$6.4851.24K
Sep 1, 2026$6.57$6.75$6.22$6.5634.98K
Aug 31, 2026$6.50$6.655$6.10$6.6155.47K
Aug 28, 2026$6.645$6.65$6.42$6.5835.02K
Aug 27, 2026$6.71$6.75$6.5501$6.5715.53K
Aug 26, 2026$7.46$7.46$6.55$6.7845.48K
Aug 25, 2026$8.075$8.10$7.91$8.0819.63K
Aug 24, 2026$7.96$8.07$7.90$8.0415.19K
Aug 21, 2026$8.03$8.21$8.03$8.044.42K
Aug 20, 2026$8.19$8.22$8.00$8.0212.48K
Aug 19, 2026$8.18$8.4999$8.18$8.3014.36K
Aug 18, 2026$8.30$8.40$7.92$8.3613.85K

Latest MBAI news

The latest Smart Investors Daily articles mentioning MBAI.

Stock researchCompany · Overview

MBAI research

Overview

Company profile and research snapshot.

Company profile

Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 10, 2026

MBody AI to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Company will hold a formal presentation and one-on-one investor meetings September 14-16, 2026 ISFIYA, Israel and LAS VEGAS, Sept. 10, 2026 (GLOBE NEWSWIRE) -- MBody AI Ltd. ("MBody AI" or the "Company") (NASDAQ: MBAI) today announced that John Fowler, Chief Executive Officer and Tim Hayden, Chief Financial Officer of MBody AI, will present at the H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-16, 2026, at the Lotte New York Palace Hotel in New York City. In

Yahoo · Sep 9, 2026

MBody AI Advances AI Robotics Rollout at Mohegan Sun

MBody AI Ltd. (NASDAQ: MBAI) completes successful Mohegan Sun pilot deployment and begins negotiation on planned commercial expansion ISFIYA, Israel and LAS VEGAS, Sept. 09, 2026 (GLOBE NEWSWIRE) -- MBody AI Ltd. ("MBody AI" or the "Company") (NASDAQ: MBAI) MBody AI Ltd. (NASDAQ: MBAI) today announced that it has successfully completed a Proof of Concept deployment of its autonomous robotic systems at Mohegan Sun, one of North America’s largest casino and entertainment destinations. The pilot ro

Yahoo · Sep 2, 2026

MBody AI Orchestrator Named Finalist for AI Deployment of the Year

MBody AI’s hardware-agnostic platform was shortlisted alongside CrowdStrike, Lenovo and CVS Health in a category recognizing real-world AI deploymentISFIYA, Israel and LAS VEGAS, Sept. 02, 2026 (GLOBE NEWSWIRE) -- MBody AI Ltd. ("MBody AI" or the "Company") (NASDAQ: MBAI) today announced that its MBody AI Orchestrator™ platform has been shortlisted for AI Deployment of the Year in The 2026 A.I. Awards. The awards program is run by The Cloud Awards. The category recognizes the most impactful and

Yahoo · Aug 28, 2026

Check-Cap Completes MBody AI Merger, Closes $10 Million Underwritten Offering

The Nasdaq-listed AI company closes its MBody AI merger; adds $10 million to scale robot deployments with Fortune 500 enterprise customersISFIYA, Israel and LAS VEGAS, Aug. 28, 2026 (GLOBE NEWSWIRE) -- Check-Cap Ltd. (the “Company” or “Check-Cap”) (NASDAQ: MBAI), an embodied artificial intelligence company, announced today the completion of its business combination with MBody AI Corp. on August 26, 2026 (the “Merger”) and the closing of its firm-commitment underwritten public offering (the “Offe

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By